Volume 15, Number 10—October 2009
Research
A Model-based Assessment of Oseltamivir Prophylaxis Strategies to Prevent Influenza in Nursing Homes
Table 1
Parameter values baseline scenario*
Parameter | Value | Reference |
---|---|---|
No. beds | 30 | |
No. HCWs | 30 | |
Time step (= shift), h | 8 | (18) |
Minimum duration of simulation, d | 80 | |
Discharge/mortality rate, per d | 1/425 | (16,17) |
Rate of becoming infectious after infection, per d | 1/1/4 | (20,21) |
Infection recovery rate, per d | 1/1/4 | (20,21) |
Prior immunity HCWs | 0.3 | (22) |
Prior immunity patients | 0 | |
Vaccine uptake patients | 75% | (25) |
Vaccine uptake HCWs | 40% | (2) |
Vaccine efficacy (against infection) | ||
Patients | 25% | (28) |
HCWs | 73% | (27) |
Transmission probability per casual contact | 0.13 | (18) |
Close/casual transmission probability ratio | 2 | |
Mean visitor frequency/patient/d | 0.7 | (31) |
Minimum duration of postexposure prophylaxis, d | 14 | (2) |
Minimum duration of postexposure prophylaxis after last detected case, d |
8 |
(2) |
Parameters in uncertainty analyses | ||
Probability of disease developing after infection (range) | 0.5 (0.30–0.7) | (4) |
Probability of disease developing after infection, during prophylaxis (range) | 0.2 (0.05–0.4) | (4) |
Oseltamivir efficacy against infection (range) | 0.53 (0.2–0.8) | (4) |
Oseltamivir reduction in infectiousness (range) | 0.2 (0–0.5) | (4) |
*HCW, healthcare worker.
References
- Cools HJ, van Essen GA. Practice guideline “Influenza prevention in nursing homes and care homes,” issued by the Dutch Society of Nursing Home Specialists; division of tasks between nursing home specialist, general practitioner and company doctor [in Dutch]. Ned Tijdschr Geneeskd. 2005;149:119–24.PubMedGoogle Scholar
- Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235. DOIPubMedGoogle Scholar
- Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004;189:440–9. DOIPubMedGoogle Scholar
- Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285:748–54. DOIPubMedGoogle Scholar
- Peters PH, Jr., Gravenstein S, Norwood P, De B, V, Van Couter A, Gibbens M, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001;49:1025–31. DOIPubMedGoogle Scholar
- Monto AS, Rotthoff J, Teich E, Herlocher ML, Truscon R, Yen HL, Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis. 2004;39:459–64. DOIPubMedGoogle Scholar
- Bowles SK, Lee W, Simor AE, Vearncombe M, Loeb M, Tamblyn S, Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999–2000. J Am Geriatr Soc. 2002;50:608–16. DOIPubMedGoogle Scholar
- Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can Commun Dis Rep. 2001;27:37–40.PubMedGoogle Scholar
- Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 2008;13:8026.
- Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med. 2009;360:953–6. DOIPubMedGoogle Scholar
- Enserink M. Infectious disease. Old drugs losing effectiveness against flu; could statins fill gap? Science. 2005;309:1976–7. DOIPubMedGoogle Scholar
- Stilianakis NI, Perelson AS, Hayden FG. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis. 1998;177:863–73.PubMedGoogle Scholar
- Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159:623–33. DOIPubMedGoogle Scholar
- Anderson R, May RM. Infectious diseases of humans: dynamics and control. New York: Oxford University Press; 1991.
- Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine. 2007;25:3066–9. DOIPubMedGoogle Scholar
- Lipsitch M, Cohen T, Murray M, Levin BR. Antiviral resistance and the control of pandemic influenza. PLoS Med. 2007;4:e15. DOIPubMedGoogle Scholar
- Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357:1373–81. DOIPubMedGoogle Scholar
- Chik KW, Li CK, Chan PK, Shing MM, Lee V, Tam JS, Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study. Hong Kong Med J. 2004;10:103–6. DOIPubMedGoogle Scholar
- Kingston BJ, Wright CV Jr. Influenza in the nursing home. Am FamPhysician. 2002;65:75–8, 72.
- Looijmans-van den Akker I, van Delden JJ, Hak E. Uptake of influenza vaccination in Dutch nursing home personnel following national recommendations. J Am Geriatr Soc. 2007;55:1486–7. DOIPubMedGoogle Scholar
- Finkelman BS, Viboud C, Koelle K, Ferrari MJ, Bharti N, Grenfell BT. Global patterns in seasonal activity of influenza A/H3N2, A/H1N1, and B from 1997 to 2005: viral coexistence and latitudinal gradients. PLoS One. 2007;2:e1296. DOIPubMedGoogle Scholar
- Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667–72. DOIPubMedGoogle Scholar
- Meijer A, Lackenby A, Hungnes O, Lina B, van der Werf S, Schwieger B, Oseltamivir-resistant influenza A (H1N1), Europe, 2007–08 season. Emerg Infect Dis. 2009;15:552–60. DOIPubMedGoogle Scholar
- Moscona A. Oseltamivir resistance—disabling our influenza defenses. N Engl J Med. 2005;353:2633–6. DOIPubMedGoogle Scholar
- Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med. 2009;6:e1000085. DOIPubMedGoogle Scholar
Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.